[Advances in the treatment of Clostridium difficile infection in children]

Area of Science:

• Gastroenterology
• Pediatric Infectious Diseases
• Microbiome Research

Background:

• Clostridium difficile infection (CDI) is a significant cause of hospital-acquired infections in children.
• Antibiotic treatment for pediatric CDI can lead to recurrence, with subsequent antibiotic therapies increasing the risk of further recurrences.
• Recurrent CDI necessitates exploring alternative treatment strategies beyond standard antibiotics.

Purpose of the Study:

• To review current research on the pathogenesis, risk factors, diagnosis, and treatment of pediatric CDI.
• To highlight fecal microbiota transplantation (FMT) as a therapeutic option for recurrent pediatric CDI.
• To provide an overview of domestic and international findings on pediatric CDI management.

Main Methods:

• Literature review of recent studies on pediatric Clostridium difficile infection.
• Analysis of data concerning the efficacy and safety of fecal microbiota transplantation in pediatric populations.
• Synthesis of information on CDI pathogenesis, risk factors, and diagnostic approaches.

Main Results:

• Fecal microbiota transplantation (FMT) has demonstrated significant efficacy in treating recurrent CDI.
• FMT exhibits a high safety profile in pediatric patients undergoing treatment for recurrent CDI.
• Antibiotic therapy remains the primary treatment but is associated with high recurrence rates.

Conclusions:

• Fecal microbiota transplantation is a promising and safe therapeutic option for children with recurrent Clostridium difficile infection.
• Further research and clinical application of FMT are warranted for managing refractory pediatric CDI.
• A comprehensive understanding of CDI pathogenesis and risk factors is crucial for effective treatment strategies.